OPKO Health $OPK Borrows Against Future Royalties
OPKO Health (NASDAQ:OPK) has secured an additional $125 million in financing by issuing senior secured notes tied to future royalties from its GLP-1 drug, mazdutide. The move allows the company to access capital early for its long-term royalty stream licensed to Eli Lilly and due to mature in 2044.
- Health (N:OPK) has secured early access to capital by leveraging its future royalty stream from mazdutide, a move that could support ongoing operations or development. - Investors in the pharmaceutical and biotech sectors may monitor similar financing structures as a means for companies to manage cash flow without diluting equity.